AC Immune Owners | StatInvestor

Health Care & Life Sciences » Biotechnology | AC Immune

AC Immune S.A. | Ownership

Companies that own AC Immune S.A.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Fidelity Management & Research Co.

3,886,249

5.77%

-183,683

06/30/2018

Fidelity (Canada) Asset Management ULC

2,594,173

3.85%

1,353,986

0.04%

06/30/2018

Duquesne Family Office LLC

2,388,700

3.55%

06/30/2018

Temasek Holdings Pte Ltd. (Investment Management)

1,337,500

1.99%

0.03%

06/30/2018

PointState Capital LP

1,000,000

1.48%

0.11%

06/30/2018

Invus Public Equities Advisors LLC

600,000

0.89%

0.19%

06/30/2018

Tekla Capital Management LLC

171,813

0.26%

0.05%

06/30/2018

FIAM LLC

156,900

0.23%

60,000

06/30/2018

Geode Capital Management LLC

51,448

0.08%

6,260

06/30/2018

Bruno Walter Finance SA

40,000

0.06%

0.36%

02/28/2018

About AC Immune

View Profile

Address	EPFL Innovation Park Lausanne Basel-Landschaft (Basle Country) 1015 Switzerland
Employees	-
Website	http://www.acimmune.com
Updated	07/08/2019
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, and Andrea Pfeifer on February 13, 2003 and is headquartered in Lausanne, Switzerland.